Skip to main content
. 2023 Jul 13;109(1):245–255. doi: 10.3324/haematol.2023.283251

Table 6.

Incidence of serious adverse events among the patients treated with the elotuzumab, pomalidomide and dexamethasone triple regimen (N=200).

graphic file with name 109245.tab6.jpg